FDA announced approval of daraxonrasib, a new targeted treatment for pancreatic cancer. CU Anschutz physician Dr. Wells Messersmith served as principal investigator.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
Daraxonrasib approved by FDA: Pancreatic cancer drug shown to improve survival
minute read
by 9News | August 31, 2026
